TY - JOUR
T1 - Pt(II) and Pd(II) derivatives of ter-butylsarcosinedithiocarbamate
T2 - Synthesis, chemical and biological characterization and in vitro nephrotoxicity
AU - Fregona, D.
AU - Giovagnini, L.
AU - Ronconi, L.
AU - Marzano, C.
AU - Trevisan, A.
AU - Sitran, S.
AU - Biondi, B.
AU - Bordin, F.
PY - 2003/1/15
Y1 - 2003/1/15
N2 - This work reports on the synthesis, characterization and biological activity of new coordination compounds of the type [M(TSDTM)X2] (M=Pt(II), Pd(II); X=Cl, Br; TSDTM=ter-butylsarcosine(S-methyl)dithiocarbamate) and [Pd(TSDT)X]n (TSDT=ter-butylsarcosinedithiocarbamate) in order to study their behavior as potential antitumor agents. All the synthesized compounds were characterized by means of elemental analysis, FT-IR, 1H and 13C-NMR spectroscopy and thermogravimetric analysis, suggesting a chelate S,S′ structure of the TSDTM/TSDT ligand in a square-planar geometry. Finally, the synthesized complexes have been tested for in vitro cytotoxic activity against human leukemic HL60 and adenocarcinoma HeLa cells; the most active compound [Pt(TSDTM)Br2], characterized by IC50 values very similar to those of the reference compound (cisplatin), was also tested for in vitro nephrotoxicity showing a very low renal cytotoxicity as compared to cisplatin itself.
AB - This work reports on the synthesis, characterization and biological activity of new coordination compounds of the type [M(TSDTM)X2] (M=Pt(II), Pd(II); X=Cl, Br; TSDTM=ter-butylsarcosine(S-methyl)dithiocarbamate) and [Pd(TSDT)X]n (TSDT=ter-butylsarcosinedithiocarbamate) in order to study their behavior as potential antitumor agents. All the synthesized compounds were characterized by means of elemental analysis, FT-IR, 1H and 13C-NMR spectroscopy and thermogravimetric analysis, suggesting a chelate S,S′ structure of the TSDTM/TSDT ligand in a square-planar geometry. Finally, the synthesized complexes have been tested for in vitro cytotoxic activity against human leukemic HL60 and adenocarcinoma HeLa cells; the most active compound [Pt(TSDTM)Br2], characterized by IC50 values very similar to those of the reference compound (cisplatin), was also tested for in vitro nephrotoxicity showing a very low renal cytotoxicity as compared to cisplatin itself.
KW - Cytotoxic activity
KW - Nephrotoxicity
KW - Palladium(II) complexes
KW - Platinum(II) complexes
UR - https://www.scopus.com/pages/publications/0037439730
U2 - 10.1016/S0162-0134(02)00571-8
DO - 10.1016/S0162-0134(02)00571-8
M3 - Article
SN - 0162-0134
VL - 93
SP - 181
EP - 189
JO - Journal of Inorganic Biochemistry
JF - Journal of Inorganic Biochemistry
IS - 3-4
ER -
